MAD2L1 and colorectal carcinoma: The results revealed that patients with CRC in the low expression groups of MAD2L1 and TOP2A exhibited significantly decreased overall survival (OS) compared to those in the high expression groups (p = 0.013 and 0.015, respectively) (Figure 7).